There has never been a greater need for better influenza (Flu) vaccines to replace traditionally produced seasonal Flu vaccines that generate variable levels of protection. Seasonal Flu vaccines are imperfect and fail from time to time resulting in huge economic costs to the NHS and other national health services in this country and globally, when they fail. There is a large global market, with WHO estimates of the world-wide influenza vaccine market to be worth $2.9-3.8 billion alone. There has never been a greater need for a new next-generation of universal influenza vaccines to replace traditionally produced seasonal Flu vaccines, with next generation Flu vaccines that also offer additional protection from pandemic influenza strains. The new innovative vaccine technology developed by DIOSynVax Ltd has the potential to change the way vaccines are made. It's unique vaccine accelerator platform utilizes novel high-throughput, computationally generated vaccines especially suited for highly variable RNA viruses like Influenza viruses. The DIOSynVax technology platform has already demonstrated impressive proof of concept pre-clinical vaccine protection against some of the most notorious haemorrhagic fever viruses such as Ebola, Lassa and Marburg viruses Based on the DIOSynVax Ltd's technology, the DIOS-HFVac3 vaccine has been selected to undergo human trials in the UK. The DIOS Digital, Immune Optimised, and Selected (DIOS) vaccine accelerator technology offers 3 key attributes needed for more effective Flu vaccines:

1.marked breadth of protection

2.accelerated development

3.depth of response and durability for sustained protection

This project will apply the proven DIOS technology to the Influenza vaccine problem. The resulting PoC data will result in improved DIOS pan-Flu prototype vaccine candidates which have the required broad immunogenicity and ultimately towards a Universal Flu vaccine protection profile against heterologous (including pandemic strains) Influenza challenges. The DIOS vaccine accelerator technology is a game-changer that has the potential to generate progress the development of dramatically improve protection of people against the broadest possible array of influenza virus threats.